O 6 -methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair enzyme, can rapidly reverse alkylation at the O 6 position of guanine by transferring the alkyl group to its cysteinyl residue.
which is highly related to the MGMT transcription suppression. 2, 3 Thus, MGMT promoter methylation implies a TMZ sensitivity status of glioma patients, confirmed in several subsequent studies and clinical trials.
4-10
Given the difficulty of detecting MGMT mRNA or protein expression directly in glioma, 11 MGMT promoter methylation testing is now wildly employed in clinical practice. Total 98 CpGs situated in the MGMT CGI, 12 named CpGs 1-98 in this study according to whose location in the 762 bps (chr10: 131264949-131265710)
from the 5′-end to the 3′-end. In early clinical trials, the methylation-specific PCR(MSP) was mainly used to determine the methylation status, and the primers of which were designed specifically to CpGs 76-80 and CpGs 84-87 fully methylated sequences, respectively. 4, 5 However, along with the high heterogeneity of the CpGs methylation gradually identified, 13, 14 MSP-based methods were unable to reflect such heterogeneity. 12, 15, 16 Currently, pyrosequencing (PSQ) has been developed to be a stable technique, offering a valid, reliable and quick evaluation of both fresh frozen and formalin fixed paraffin embedded (FFPE) specimens. 11, 13, 14, [17] [18] [19] [20] [21] [22] Similar to the MSP method, PSQ determines the MGMT promoter methylation by the mean methylation level of several selected consecutive CpGs. 11, 15, 23 The methylation statuses of CpGs and 72-90 are proved highly correlated to MGMT transcription, and
CpGs 72-90 seems to play a more critical role. 12, 24 However, the high heterogeneity of different CpGs' methylation level is also recognized, 12, 16, 24 how many CpGs in the MGMT CGI is robust enough to reflect the transcription status is still a controversial issue for MGMT methylation PSQ testing. 14, 15 Various number of CpGs from four to eighteen has been used as CpG combinations in reported studies ( Figure 1 ). 11, [13] [14] [15] 17, 20, 25, 26 Among which, the commonly adopted combinations are CpGs 
| MATERIAL S AND ME THODS

| Patients and samples
| DNA isolation and bisulfite modification
Genomic DNA was extracted from freshly frozen tumor tissue with the QIAamp DNA Mini Kit (Qiagen, Stockach, Germany). The DNA concentration and quality were determined by a Nano-Drop ND-1000 spectrophotometer (NanoDrop Technologies, Houston, TX, USA).
And then the bisulfite conversion used 100 ng DNA and an Epitect Bisulfite kit (Qiagen) according to the manufacturer's protocol.
| PSQ testing
The template used in the MGMT PSQ testing was prepared as previously described. 17, 27 Briefly, bisulfite-treated DNA was preamplified 
| RNA sequencing (RNA-seq), quality control, and mRNA expression calculation
RNA sequencing library was constructed as previously published study. 28 Briefly, RNA was extracted from the frozen tissue sample, and the RNA-seq library was constructed and subsequently se- were converted into sequence data using base calling software (Illumina pipeline CASAVA v1.8.2, CA, USA) and then further estimated by standard quality control criteria.
Sequencing reads were excluded when any one of the following parameters fitted: (a) the read is aligned to adaptor or primer with no more than two mismatches; (b) the read contains over 10% unknown bases;
F I G U R E 2 Correlation of MGMT mRNA expression to the methylation level of MGMT promoter individual CpG or CpG combinations. A and B, The methylation level of individual CpG or CpG combinations is applied to heatmap in the eight-site cohort (A) and the seven-site cohort (B). The methylation level of a CpG combination is the average methylation level of all CpGs included in this combination. "r" is the Spearman r value, and the 95% confidence interval of the "r" is shown in the following bracket, respectively. ****P < 0.0001 and (c) the read includes more than 50% of low-quality bases (quality value ≤5). The detailed information of the quality control for the whole RNA sequencing database had been described in our previous study. 29 The MGMT mRNA expression level was calculated following the 
| Statistical analysis
Statistical analysis was performed with R (https://www.r-project.
org/, v3.4.1), and GraphPad Prism 7 (GraphPad Software, the state of California, USA). 0.05 was chosen to be the significance cutoff for Pvalue. The relationship between methylation level of CpGs and MGMT mRNA expression was analyzed by Spearman's correlation analysis.
The patients were stratified into two groups according to their MGMT mRNA expression (using the median expression as the cutoff), and the receiver operating characteristic (ROC) analysis was employed to evaluate the predictive value of MGMT promoter methylation status on the mRNA expression level by calculating the area under the curve (AUC).
The ROC analysis was also used to evaluate the predictive value of MGMT promotor methylation status for patients' survival. The median OS was used to stratified the patients. Kaplan-Meier step was used to estimating the survival of subgrouped patients, and the value between groups was compared by the log-rank test. Table S2 ).
| RE SULTS
In the seven-site cohort, CpGs 72-78 were tested, and the CpGs 74-78 combination is currently used in the commercial kit (Qiagen, 972032, and 970032). Based on the similar strategy used in the eight-site cohort, all individual CpG, representative two-CpG combination (CpGs 75 and 77), all three or four CpG combinations within CpGs 74-78 combination, and all consecutive five, six, and seven CpG combinations were finally selected for investigation ( Figure 2B and Supporting Information Table S2 ).
We presented the methylation level of each individual CpG and Thus, we inferred that CpG combinations with more four or more
CpGs have similar predictive value on MGMT mRNA expression.
| Predictive value of each individual CpG and selected CpG combinations methylation level for MGMT mRNA expression
To verify our inference, we further compared the predictive value Figure S1 ). For the predictive and prognostic roles of MGMT methylation in WHO grade III glioma patients have been reported, 9 the results indicated that all the selected CpG combinations in the eight-site and the seven-site cohort had similar predictive value.
| Therapeutic prognostic effects of the selected CpG combinations in glioblastoma
| D ISCUSS I ON
The PSQ testing has been regarded as the gold standard forMGMT promoter methylation testing and wildly used in reported studies and clinical practice. The cutoff value is another important issue for theMGMT PSQ testing. Here, we found that the optimal cutoff for the mean methylation level of different CpG combinations varied obviously. This is consistent with previous studies, where the cutoff varied from 2.68% to 30% for different CpG combinations. 14,17,23-26 Some studies even suggested that there may be a "gray zone" between the true methylated status and true un-methylated status, and the cutoff value around 10% used in most studies was overestimated. 25, 26 We also noticed that the cutoff of the mean methylation level cannot be easily determined, and the different cutoff for the same CpG combination was used in different studies. 13, 14, 17, 33 Recently, a study indicated that the optimal cutoff should not only be determined by the ROC likelihood value but also by the sensitivity and specificity. 17 Thus, we determined the cutoff in this study by similar strategy, comprehensively considering the ROC likelihood value, sensitivity, specificity, and cutoffs used in reported studies. However, a more comprehensive and targeted study is still required for the optimal cutoff determination for MGMT methylation PSQ testing. 
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